The document discusses cancer and the immune system. It explains that cancer arises from mutations in normal genes and describes different types of cancers like carcinomas, sarcomas, and leukemias. It then discusses how the immune system normally protects against cancer through mechanisms like antigen presentation and cytotoxic T cells. However, tumors can evade the immune system through processes such as decreasing MHC expression and producing immunosuppressive proteins. Immunotherapy aims to boost the immune response against cancer and involves approaches like immune checkpoint inhibitors, cytokines, and tumor vaccines.
Therapeutic prospects in Cancer Immunotherapy.
Interleukins for Renal Cell Carcinoma.
BCG for Bladder Cancer.
Vaccination Strategies: Oncolytic virus for melanoma, Dendritic Cell therapy for CA Prostate.
Immune Checkpoint inhibitors. PD1 and PD L1 inhibitors.
Adoptive Cell Therpay. CAR T Cell Therapy
Clinical efficacy. Costs.
The organism possesses powerful mechanism to avoid immune auto aggression, The acquired ability of the immune system to avoid responsiveness to self antigens is defined as ‘ tolerance’ It is obtained by the cooperative efforts of central and peripheral mechanisms, which allow a rapid and efficient removal of pathogens ( Virus and Bacteria ) in the absence of self-recognition, It is a dysfunction of the immune system. The immune system protects you from disease and infection. Sometimes, though, the immune system can produce autoantibodies that attack healthy cells, tissues, and organs. This can lead to autoimmune disease.Autoimmune diseases can affect any part of the body
Therapeutic prospects in Cancer Immunotherapy.
Interleukins for Renal Cell Carcinoma.
BCG for Bladder Cancer.
Vaccination Strategies: Oncolytic virus for melanoma, Dendritic Cell therapy for CA Prostate.
Immune Checkpoint inhibitors. PD1 and PD L1 inhibitors.
Adoptive Cell Therpay. CAR T Cell Therapy
Clinical efficacy. Costs.
The organism possesses powerful mechanism to avoid immune auto aggression, The acquired ability of the immune system to avoid responsiveness to self antigens is defined as ‘ tolerance’ It is obtained by the cooperative efforts of central and peripheral mechanisms, which allow a rapid and efficient removal of pathogens ( Virus and Bacteria ) in the absence of self-recognition, It is a dysfunction of the immune system. The immune system protects you from disease and infection. Sometimes, though, the immune system can produce autoantibodies that attack healthy cells, tissues, and organs. This can lead to autoimmune disease.Autoimmune diseases can affect any part of the body
Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers.
Immunotherapeutics (Types of immunotherapeutics, humanisation antibody therap...NikitaBankoti2
Immunotherapy
➢ Treatment to stimulate or restore the ability of the immune (defence) system to fight
against infection or disease.
➢ It is also sometimes called Biologic therapy or Biotherapy.
➢ Biological therapy is thus any form of treatment that uses the body’s natural abilities
that constitute the immune system to fight infection and disease or to protect the body
from some of the side effects of treatment e.g. – cancer.
Types of Immunotherapeutics
1. Monoclonal antibody
2. Cancer vaccines therapy
3. Immune checkpoint inhibitors
4. Non-specific Immunotherapies
5. Chimeric antigen receptor (CAR) T-cell therapy
Humanized Antibody- They are antibodies from non-human species whose protein sequences have
been modified to increase their similarity to antibody variants produced naturally in humans.
➢The process of humanization is usually applied to monoclonal antibodies developed for administration
to humans. (e.g- antibodies developed as anti-cancer drugs)
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...DanBrown980551
Do you want to learn how to model and simulate an electrical network from scratch in under an hour?
Then welcome to this PowSyBl workshop, hosted by Rte, the French Transmission System Operator (TSO)!
During the webinar, you will discover the PowSyBl ecosystem as well as handle and study an electrical network through an interactive Python notebook.
PowSyBl is an open source project hosted by LF Energy, which offers a comprehensive set of features for electrical grid modelling and simulation. Among other advanced features, PowSyBl provides:
- A fully editable and extendable library for grid component modelling;
- Visualization tools to display your network;
- Grid simulation tools, such as power flows, security analyses (with or without remedial actions) and sensitivity analyses;
The framework is mostly written in Java, with a Python binding so that Python developers can access PowSyBl functionalities as well.
What you will learn during the webinar:
- For beginners: discover PowSyBl's functionalities through a quick general presentation and the notebook, without needing any expert coding skills;
- For advanced developers: master the skills to efficiently apply PowSyBl functionalities to your real-world scenarios.
JMeter webinar - integration with InfluxDB and GrafanaRTTS
Watch this recorded webinar about real-time monitoring of application performance. See how to integrate Apache JMeter, the open-source leader in performance testing, with InfluxDB, the open-source time-series database, and Grafana, the open-source analytics and visualization application.
In this webinar, we will review the benefits of leveraging InfluxDB and Grafana when executing load tests and demonstrate how these tools are used to visualize performance metrics.
Length: 30 minutes
Session Overview
-------------------------------------------
During this webinar, we will cover the following topics while demonstrating the integrations of JMeter, InfluxDB and Grafana:
- What out-of-the-box solutions are available for real-time monitoring JMeter tests?
- What are the benefits of integrating InfluxDB and Grafana into the load testing stack?
- Which features are provided by Grafana?
- Demonstration of InfluxDB and Grafana using a practice web application
To view the webinar recording, go to:
https://www.rttsweb.com/jmeter-integration-webinar
Essentials of Automations: Optimizing FME Workflows with ParametersSafe Software
Are you looking to streamline your workflows and boost your projects’ efficiency? Do you find yourself searching for ways to add flexibility and control over your FME workflows? If so, you’re in the right place.
Join us for an insightful dive into the world of FME parameters, a critical element in optimizing workflow efficiency. This webinar marks the beginning of our three-part “Essentials of Automation” series. This first webinar is designed to equip you with the knowledge and skills to utilize parameters effectively: enhancing the flexibility, maintainability, and user control of your FME projects.
Here’s what you’ll gain:
- Essentials of FME Parameters: Understand the pivotal role of parameters, including Reader/Writer, Transformer, User, and FME Flow categories. Discover how they are the key to unlocking automation and optimization within your workflows.
- Practical Applications in FME Form: Delve into key user parameter types including choice, connections, and file URLs. Allow users to control how a workflow runs, making your workflows more reusable. Learn to import values and deliver the best user experience for your workflows while enhancing accuracy.
- Optimization Strategies in FME Flow: Explore the creation and strategic deployment of parameters in FME Flow, including the use of deployment and geometry parameters, to maximize workflow efficiency.
- Pro Tips for Success: Gain insights on parameterizing connections and leveraging new features like Conditional Visibility for clarity and simplicity.
We’ll wrap up with a glimpse into future webinars, followed by a Q&A session to address your specific questions surrounding this topic.
Don’t miss this opportunity to elevate your FME expertise and drive your projects to new heights of efficiency.
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered QualityInflectra
In this insightful webinar, Inflectra explores how artificial intelligence (AI) is transforming software development and testing. Discover how AI-powered tools are revolutionizing every stage of the software development lifecycle (SDLC), from design and prototyping to testing, deployment, and monitoring.
Learn about:
• The Future of Testing: How AI is shifting testing towards verification, analysis, and higher-level skills, while reducing repetitive tasks.
• Test Automation: How AI-powered test case generation, optimization, and self-healing tests are making testing more efficient and effective.
• Visual Testing: Explore the emerging capabilities of AI in visual testing and how it's set to revolutionize UI verification.
• Inflectra's AI Solutions: See demonstrations of Inflectra's cutting-edge AI tools like the ChatGPT plugin and Azure Open AI platform, designed to streamline your testing process.
Whether you're a developer, tester, or QA professional, this webinar will give you valuable insights into how AI is shaping the future of software delivery.
Search and Society: Reimagining Information Access for Radical FuturesBhaskar Mitra
The field of Information retrieval (IR) is currently undergoing a transformative shift, at least partly due to the emerging applications of generative AI to information access. In this talk, we will deliberate on the sociotechnical implications of generative AI for information access. We will argue that there is both a critical necessity and an exciting opportunity for the IR community to re-center our research agendas on societal needs while dismantling the artificial separation between the work on fairness, accountability, transparency, and ethics in IR and the rest of IR research. Instead of adopting a reactionary strategy of trying to mitigate potential social harms from emerging technologies, the community should aim to proactively set the research agenda for the kinds of systems we should build inspired by diverse explicitly stated sociotechnical imaginaries. The sociotechnical imaginaries that underpin the design and development of information access technologies needs to be explicitly articulated, and we need to develop theories of change in context of these diverse perspectives. Our guiding future imaginaries must be informed by other academic fields, such as democratic theory and critical theory, and should be co-developed with social science scholars, legal scholars, civil rights and social justice activists, and artists, among others.
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Jeffrey Haguewood
Sidekick Solutions uses Bonterra Impact Management (fka Social Solutions Apricot) and automation solutions to integrate data for business workflows.
We believe integration and automation are essential to user experience and the promise of efficient work through technology. Automation is the critical ingredient to realizing that full vision. We develop integration products and services for Bonterra Case Management software to support the deployment of automations for a variety of use cases.
This video focuses on the notifications, alerts, and approval requests using Slack for Bonterra Impact Management. The solutions covered in this webinar can also be deployed for Microsoft Teams.
Interested in deploying notification automations for Bonterra Impact Management? Contact us at sales@sidekicksolutionsllc.com to discuss next steps.
UiPath Test Automation using UiPath Test Suite series, part 3DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 3. In this session, we will cover desktop automation along with UI automation.
Topics covered:
UI automation Introduction,
UI automation Sample
Desktop automation flow
Pradeep Chinnala, Senior Consultant Automation Developer @WonderBotz and UiPath MVP
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
Let's dive deeper into the world of ODC! Ricardo Alves (OutSystems) will join us to tell all about the new Data Fabric. After that, Sezen de Bruijn (OutSystems) will get into the details on how to best design a sturdy architecture within ODC.
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
Empowering NextGen Mobility via Large Action Model Infrastructure (LAMI): pav...
Cancer immuno therapy
1.
2. The division of normal cells is precisely controlled. New
cells are only formed for growth or to replace dead ones.
Cancerous cells divide repeatedly out of control even though
they are not needed, they crowd out other normal cells and
function abnormally. They can also destroy the correct
functioning of major organs.
3. Cancer arises from the mutation of a normal gene.
Mutated genes that cause cancer are called oncogene.
It is thought that several mutations need to occur to give rise
to cancer
Cells that are old or not functioning properly normally self
destruct and are replaced by new cells.
Any agent that causes cancer is called a carcinogen and is
described as carcinogenic.
So some mutagens are carcinogenic.
4. SARCOMAS
Develop in the connective and supporting tissue e.g. muscle, cartilage, bones , fatty
tissues.
Often very malignant increasing rapidly in size and invading neighboring tissues.
Can develop in children. under 20 approximately.
MELANOMAS;
Type of skin cancer often occurring on legs , neck , head.
Often spread rapidly.
It can develop from abnormal moles.
Melanomas are usually brown or black, but can appear pink, tan, or even white.
5. Teratomas
Arise from the embryonic cell that may be present in the
ovary , testicles and other areas.
Leukemias or Cancer of blood
In this bone marrow produce too many white blood cells
that do not die off in this way that normal aging blood
cells do . instead they keep dividing and ultimately take
over healthy red blood cell, which our body depend on for
the normal oxygen and nutrient transport.
6. Carcinomas
Develop from the epithelial cell , such as inside of the
cheek or lining of the intestine.
Can occur in many regions of the body glands , ducts
,mucous membrane.
(esophagus , colon , stomach , intestine)
Lymphomas
cancers of the lymphatic system.
7.
8. Proto-oncogene; It is a normal gene which regulate
programmed cell death and give signal that lead to cell
division.
Proto-oncogene is converted to oncogene (the gene that
has potential to cause cancer) by
• Mutation
• Chromosomal translocation
9. Cancer cell continue to divide and accumulate form a
tumor
Some cell from primary cancer break through and travel to
distant sites by mean of :
-invasion
-blood circulation
-Lymphatic system
Cancer cell spread to other parts of body called metastasis.
10.
11. Both humoral and cell mediated immunity play a role against abnormal cell,viruses and bacteria.
Humoral immunity
B cell triggered when it encounters its matching antigens
B cell engulf the antigen and digest it
It display antigen fragments bound to its unique MHC molecules
This combination of antigen and MHC attract the help of a mature matching T cell
Cytokines secreted by the T cell help the B cell to multiply and mature into antibody producing Plasma
cell
It went to blood and antibody lock onto matching antigen and antigen antibody complex are cleared by
complement cascade
12. The activation phase begins
when an antigen-presenting cell
of the host organism encounters
and attacks an invading virus.
. The processed antigens
combine with MHC class II
proteins and are presented on
the surface of the APC.
A helper T cell recognizes the
displayed antigen on the APC
and binds to the MHC class II
protein-antigen complex.
The activated helper T cell
releases chemical messengers
such as the cytokine IL-2 and
gamma interferon (IFN-g
Cytotoxic t cell recognized by
MHC I protein antigen complex
on the infected epithelial cell.
Cytokines also attract NK cells
to the site of infection.
The activated cytotoxic T cell
binds to the MHC class I protein
antigen complex on the surface
of the infected epithelial cell
which release a potent chemical
called Perforin which cause lysis
of cell
13. The immune system recognizes and destroys tumor cells
that are constantly arising during the life of the individual
IFN-gamma and lymphocytes prevent primary tumor
development and shape tumor immunogenicity
14.
15. One way is by recognizing stressed cells is stressed cell in
your body will show it on the cell surface. There are some
stress markers and that will be recognized by the immune
system and the immune system will simply kill the
stressed cells.
the immune system is able to recognize mutations in self -
mutations that are required for normal cells to become a
cancer cell.
17. Tumor Cells Frequently Express Low Levels of Class I
MHC Molecules.
The decrease in class I MHC expression can be
accompanied by progressive tumor growth, and so the
absence of MHC molecules on a tumor is generally an
indication of a poor prognosis. The immune response itself
may play a role in selecting tumor cells with decreased
class I MHC expression
18.
19. Antitumor antibody itself acts as a blocking factor.
Presumably the antibody binds to tumor-specific antigens
and masks the antigens from cytotoxic T cells
Immune complexes have been shown to block the CTL
response
20. Without sufficient numbers of antigen-presenting
cells in the immediate vicinity of a tumor, the T
cells will receive only a partial activating signal
21. Loss of Antigen Variant: Loss of Antigen Variant result
in that the T cell did not recognize Tumor.
Production of immunosuppressive protein: result in
inhibition of T cell activation
22.
23.
24. » Treatment that uses certain parts of the immune system to fight
diseases such as cancer.
» Stimulating your own immune system to work harder or smarter to
attack cancer cells.
» In late 1800s, Dr William Coley treated cancer patients by
infecting them with certain kinds of bacteria, which came to be
known as Coley toxins.
» Giving you immune system components, such as man-made
immune system proteins.
» Immunotherapy is a type of cancer treatment which helps to boost
body’s natural defenses to fight the cancer, infection, and other
diseases or can be defined as the treatment of disease by stimulating
the body's production of antibodies; it is also known as biological
therapy.
25. Different forms of immunotherapy may be given in different ways.
These include:
Intravenous: The immunotherapy goes directly into a vein.
Oral: The immunotherapy comes in pills or capsules that you swallow.
Topical: The immunotherapy comes in a cream that you rub onto your skin. This
type of immunotherapy can be used for very early skin cancer.
Intravesical: The immunotherapy goes directly into the bladder.
26. Non specific immunotherapies
Immune checkpoint inhibitors
Specific immunotherapy
Tumor vaccines
27. Also called biological response modifiers.
Treatments to stimulate the immune system in a general way to increase
activity against cancer cells
stimulate immune system in a general way but still can be good response
against cancer cells
Some examples include man-made versions of cytokines, a chemical in
immune cells, such as interleukins and interferon’s.
28. » Injected either under skin, muscle or intravenous. cytokines are
divide into name of two chemicals named interleukins and
interferons
» Interleukins helps the cells to divide rapidly. they are made in laboratory
called interleukin-2, or aldesleukin.and used for treatment of kidney and
skin cancer. it can be combined with chemotherapy such as interferon-
Alfa. Other interleukins, such as IL-7, IL-12, and IL-21, are now being
studied for use against cancer.
» Interferons help to fight cancer and may help to slow the growth of
cancer cells. An interferon is made in laboratory, named as IFN-Alfa,
IFN-beta, and IFN-gamma
29. Immune system depends on multiple check points or immunological
brakes to avoid over activation of the immune system on healthy cell.
Tumor cells target molecules like PD-1, PD-L1, and CTLA-4. PD-1 is a
checkpoint protein on T cells. It normally acts as a type of “off switch”
that helps keep the T cells from attacking other cells in the body. It does
this when it attaches to PD-L1, a protein on some normal cells. When
PD-1 binds to PD-L1, it basically tells the T cell to leave the other cell
alone. Some cancer cells have large amounts of PD-L1, which helps them
evade immune attack
These inhibitors target either PD-1 or PD-L1 can boost the immune
response against cancer cells and have shown a great deal of promise in
treating certain cancers.
30. Thalidomide, lenalidomide, and pomalidomide, they are known as
immunomodulating drugs (or IMiDs). These drugs are used to
treat multiple myeloma and some other cancers.
Certain bacteria's called Bacille Calmette-Guerin is a germ that
helps activate immune system. BCG was one of the earliest
immunotherapies used against cancer. BCG used to treat bladder
cancer and some melanoma skin cancers by injecting it directly into
the tumors
One more drug named Imiquimod used as a cream on skin. It
stimulates immune response against skin cancer cells and is used to
treat some early stage skin cancers (or pre-cancers)
31.
32. The actual transfer of components of immune system which
are already capable of directing an immune response.
Antibody therapy: MAB's constitute of pure population of
immune system proteins that attack specific molecular targets.
When tipped with radioactive isotopes can home in on tumor
cells and deliver quick results.
Work by activation of compliment system.
To mark cells fir destruction.
33. Cause an anti-proliferative effect by attaching to the
target tumor cells.
Useful in causing apoptosis of the tumor cells too.
Large population if MAB 's can be created in order to
specifically attain a target response against the tumor cells.
34. Transfer of antigen specific T-cells
After isolation from a cancer patient
Expansion in test tube
Re infusion back into patient
Draw back : short life span
35. Whole tumor cells extracted from patient.
Blasted with radiations to weaken them.
Adjuvants added to cause friendly environment within
patient for representation of antigen to immune system.